← Back to Search

Monoclonal Antibodies

Participants with Mantle Cell Lymphoma for Mantle Cell Lymphoma

Phase 1

Recruiting

Led By Anita Kumar, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Previously treated with at least one prior line of systemic therapy for mantle cell lymphoma. Prior BTKi failure is required

Presence of evaluable disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is trying to determine if using a combination of glofitamab and lenalidomide can effectively treat people with Mantle Cell Lymphoma that has come back or is not responding

Who is the study for?

This trial is for people with Mantle Cell Lymphoma that has come back or didn't respond to previous treatments. The specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have a particular stage of the disease.Check my eligibility

What is being tested?

The study is testing if combining two drugs, Glofitamab and Lenalidomide, can effectively treat Mantle Cell Lymphoma. It might also involve Obinutuzumab as part of the treatment regimen.See study design

What are the potential side effects?

While specific side effects aren't listed here, common ones for cancer treatments like Glofitamab and Lenalidomide include fatigue, nausea, risk of infection due to low blood cell counts, rash or other skin reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had treatment for mantle cell lymphoma and it included a BTK inhibitor which did not work.

Select...

My cancer can be measured or observed.

Select...

My cancer cells show CD20 according to my hospital's tests.

Select...

I am able to get out of my bed or chair and move around.

Select...

My diagnosis is mantle cell lymphoma, confirmed by WHO guidelines.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of participants who successfully receive glofitamab

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with Mantle Cell LymphomaExperimental Treatment3 Interventions

Participants will be diagnosed with relapsed, refractory (R/R) mantle cell lymphoma (MCL) with prior BTK inhibitor (BTKi) failure

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lenalidomide

2005

Completed Phase 3

~1480

Glofitamab

2021

Completed Phase 1

~60

Obinutuzumab

2015

Completed Phase 3

~3250

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,859 Total Patients Enrolled

Genentech, Inc.Industry Sponsor

1,541 Previous Clinical Trials

568,104 Total Patients Enrolled

Anita Kumar, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

6 Previous Clinical Trials

764 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At how many distinct venues is this scientific experiment currently being conducted?

"Among the 10 available locations for this trial, notable institutions include Memorial Sloan Kettering Cancer Center in New york (where all protocol activities will take place), Mayo Clinic in Rochester (which will be involved in data collection only), and Washington University in Saint Louis (also participating solely in data collection). Additionally, there are 7 other sites where patients can potentially participate."

Answered by AI

Are prospective patients still eligible to participate in this ongoing medical study?

"According to the information provided on clinicaltrials.gov, this particular study is not currently seeking participants. It was first posted on March 1st, 2024 and last updated on December 21st, 2023. However, it's worth noting that there are currently 1643 other trials actively searching for eligible candidates."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

2024. "A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06192888.

All > Mantle Cell Lymphoma > Paid Studies Minneapolis